Objective： To evaluate the clinical application of proton magnetic resonance spectroscopy （1HMRS） in patients with radiotherapy treated intracranial tumors. Methods： Forty patients with intracranial tumors underwe...Objective： To evaluate the clinical application of proton magnetic resonance spectroscopy （1HMRS） in patients with radiotherapy treated intracranial tumors. Methods： Forty patients with intracranial tumors underwent multivoxel 1HMRS examination before and after radiotherapy. The concentrations of N-acetyl aspartate （NAA）, choline （Cho） and creatine （Cr） were obtained both in the tumors and the contralateral normal brain regions, The ratios of NANCr, Cho/Cr and Cho/NAA were calculated at the same time and follow-up one year. Results： （1） After radiotherapy, tumors inhibited by radiation had decreased Cho, NAA and Cr on proton MRS. Some cases showed necrotic wave. （2） During the one year follow-up, local tumor recurred in 8 cases and their Cho and Cho/NAA increased high again. Other cases without recurrence, HMRS showed no change. Conclusion： Multivoxel proton MR spectroscopy is available for study of tumor metabolites after radiotherapy and it is a valuable method in the evaluation of radiotherapy treated tumors,展开更多
Objective： To explore water soluble metabolite features of brain tumor specimens with HRMAS-^1HMRS and its potential clinical value. Methods： There were thirty cases of pathologically proven brain tumor, including 6...Objective： To explore water soluble metabolite features of brain tumor specimens with HRMAS-^1HMRS and its potential clinical value. Methods： There were thirty cases of pathologically proven brain tumor, including 6 Ⅰ-Ⅱ grade astrocytomas, 7 Ⅲ grade anaplastic astrocytomas, 10 IV grade glioblastomas and 7 meningiomas. Used Varian Company 600 MHz spectrometer with the Nano-probe for acquisition HRMASJHMRS, which was postprocessed with jMRUI 3.2 version software. These metabolic probability and their ratios to Cr were summed. Results： （1） HRMAS-^1HMRS could resolve NAA, PCr/Cr, GPC ± PCho ± Cho, Glu/GIn, Gly, Tau, Ala, Lac, ml and so on. All samples showed Lac, 6 samples showed unknown single peak at 3.72 ppm or 3.90 ppm. （2） The mean Cho/Cr of 6 Ⅰ-ⅡI grade astrocytomas was 2.42 ± 1.01 （P = 0.003, compared with glioblastoma）. The mean Cho/Cr of 7 anaplastic astrocytomas was 3.48 ± 0.59 （P = 0.01, compared with glioblastoma）. The Cho/Cr of 10 glioblastomas broadly ranged from 0.9 to 11.3 （mean 5.40 ± 1.23）. From Ⅰ-Ⅱ grade astrocytoma to glioblastoma, Ala/Cr, Tau/Cr and Gly/Cr trends were increased; the mean Ala/Cr of glioma was 0.31 ± 0.13. （3） Meningiomas showed higher Ala and Cho. Their Cr was lower than that of gliomas. 4/7 cases had no NAA, 3/7 patients had lower NAA. Mean Cho/Cr was 3.56 ± 1.01, Ala/Cr was 0.53 ±0.28 （P = 0.006, compared with glioma）. Conclusion： HRMAS-^1HMRS can show further details in vivo MRS, resolve in vivo spectroscopic metabolite of Cho compound and differentiate the extent of benign and malignant glioma. With the increase in the malignant degree of gliomas, Cho, ml, Ala, Tau and Gly will increase. HRMAS-^1HMRS is the only method of isotropic spectroscopy for pathological specimens.展开更多
Proton magnetic resonance spectroscopy (1H MRS) can provide specific biochemical information within breast lesions and the elevated composite choline concentration as a useful diagnostic tool has been used to distingu...Proton magnetic resonance spectroscopy (1H MRS) can provide specific biochemical information within breast lesions and the elevated composite choline concentration as a useful diagnostic tool has been used to distinguish malignant from benign breast lesions, early evaluate response to therapy and predict prognosis. However, several obstacles including poor spatial resolution, low signal-to-noise ratio (SNR), long acquisition time and the difficulty of "extra" lipid suppression may have a negative impact on the routine application of in vivo 1H MRS for human breast cancer. At present, optimization H MRS methodology for breast studies has been performed.展开更多
基金a grant from the Medical Foundation of Wu Jieping(No.32067000501).
文摘Objective： To evaluate the clinical application of proton magnetic resonance spectroscopy （1HMRS） in patients with radiotherapy treated intracranial tumors. Methods： Forty patients with intracranial tumors underwent multivoxel 1HMRS examination before and after radiotherapy. The concentrations of N-acetyl aspartate （NAA）, choline （Cho） and creatine （Cr） were obtained both in the tumors and the contralateral normal brain regions, The ratios of NANCr, Cho/Cr and Cho/NAA were calculated at the same time and follow-up one year. Results： （1） After radiotherapy, tumors inhibited by radiation had decreased Cho, NAA and Cr on proton MRS. Some cases showed necrotic wave. （2） During the one year follow-up, local tumor recurred in 8 cases and their Cho and Cho/NAA increased high again. Other cases without recurrence, HMRS showed no change. Conclusion： Multivoxel proton MR spectroscopy is available for study of tumor metabolites after radiotherapy and it is a valuable method in the evaluation of radiotherapy treated tumors,
文摘Objective： To explore water soluble metabolite features of brain tumor specimens with HRMAS-^1HMRS and its potential clinical value. Methods： There were thirty cases of pathologically proven brain tumor, including 6 Ⅰ-Ⅱ grade astrocytomas, 7 Ⅲ grade anaplastic astrocytomas, 10 IV grade glioblastomas and 7 meningiomas. Used Varian Company 600 MHz spectrometer with the Nano-probe for acquisition HRMASJHMRS, which was postprocessed with jMRUI 3.2 version software. These metabolic probability and their ratios to Cr were summed. Results： （1） HRMAS-^1HMRS could resolve NAA, PCr/Cr, GPC ± PCho ± Cho, Glu/GIn, Gly, Tau, Ala, Lac, ml and so on. All samples showed Lac, 6 samples showed unknown single peak at 3.72 ppm or 3.90 ppm. （2） The mean Cho/Cr of 6 Ⅰ-ⅡI grade astrocytomas was 2.42 ± 1.01 （P = 0.003, compared with glioblastoma）. The mean Cho/Cr of 7 anaplastic astrocytomas was 3.48 ± 0.59 （P = 0.01, compared with glioblastoma）. The Cho/Cr of 10 glioblastomas broadly ranged from 0.9 to 11.3 （mean 5.40 ± 1.23）. From Ⅰ-Ⅱ grade astrocytoma to glioblastoma, Ala/Cr, Tau/Cr and Gly/Cr trends were increased; the mean Ala/Cr of glioma was 0.31 ± 0.13. （3） Meningiomas showed higher Ala and Cho. Their Cr was lower than that of gliomas. 4/7 cases had no NAA, 3/7 patients had lower NAA. Mean Cho/Cr was 3.56 ± 1.01, Ala/Cr was 0.53 ±0.28 （P = 0.006, compared with glioma）. Conclusion： HRMAS-^1HMRS can show further details in vivo MRS, resolve in vivo spectroscopic metabolite of Cho compound and differentiate the extent of benign and malignant glioma. With the increase in the malignant degree of gliomas, Cho, ml, Ala, Tau and Gly will increase. HRMAS-^1HMRS is the only method of isotropic spectroscopy for pathological specimens.
文摘Proton magnetic resonance spectroscopy (1H MRS) can provide specific biochemical information within breast lesions and the elevated composite choline concentration as a useful diagnostic tool has been used to distinguish malignant from benign breast lesions, early evaluate response to therapy and predict prognosis. However, several obstacles including poor spatial resolution, low signal-to-noise ratio (SNR), long acquisition time and the difficulty of "extra" lipid suppression may have a negative impact on the routine application of in vivo 1H MRS for human breast cancer. At present, optimization H MRS methodology for breast studies has been performed.
